The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County
Open accessAbstract
Background: Several placebo controlled studies have demonstrated the efficacy of infliximab in inflammatory bowel disease (IBD) but the potential toxicity of this new biological compound has been less studied. Aim: To assess the use of infliximab in IBD in a population based cohort, with special emphasis on the occurrence of severe adverse events and mortality. Patients: All patients with IBD treated with infliximab between 1999 and 2001 in Stockholm County were evaluated. Methods: Prospective registration of clinical data was carried out. Retrospective analyses were made of possible adverse events occurring in relation to infliximab treatment. Adverse events requiring pharmacological treatment or hospitalisation were defined as severe. Clinical response was assessed as remission, response, or failure. Results: A cohort comprising 217 patients was assembled: 191 patients had Crohn’s disease (CD), and infliximab was used off label for ulcerative colitis (UC) in 22 patients. Four patients were treated for indeterminate colitis (IC). Mean age was 37.6 (0.9) years (range 8–79). The mean number of infliximab infusions was 2.6 (0.1) (range 1–11). Forty two severe adverse events were registered in 41 patients (CD, n = 35). Eleven of the severe adverse events occurred postoperatively (CD, n = 6). Three patients with CD developed lymphoma (of which two were fatal), opportunistic infections occurred in two patients (one with UC, fatal), and two patients with severe attacks of IBD died due to sepsis (one with CD, one postoperatively with UC). One additional patient with UC died from pulmonary embolism after colectomy. Mean age in the group with fatal outcome was 62.7 years (range 25–79). The overall response rate was 75% and did not differ between the patient groups. Conclusions: Infliximab was efficacious as an anti-inflammatory treatment when assessed in a population based cohort of patients with IBD. However, there appear to be a significant risk of deleterious and fatal adverse events, particularly in elderly patients with severe attacks of IBD. Off label use of infliximab in UC and IC should be avoided until efficacy is proven in randomised controlled trials. The underlying risk of developing malignancies among patients with severe or chronically active CD in need of infliximab treatment is not known but the finding of a 1.5% annual incidence of lymphoma emphasises the need for vigilant surveillance with respect to this malignant complication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Brown, S. L., Greene, M. H., Gershon, S. K., Edwards, E. T., & Braun, M. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10679 · Cited by 655
Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study
Sands, B. E., Tremaine, W. J., Sandborn, W. J., Rutgeerts, P. J., Hanauer, S. B., Mayer, L., Targan, S. R., & Podolsky, D. K. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200105000-00001 · Cited by 422
Probert, C. S. J., Hearing, S. D., Schreiber, S., Kühbacher, T., Ghosh, S., Arnott, I. D. R., & Forbes, A. (2003) · Gut · doi:10.1136/gut.52.7.998 · Cited by 355
Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy
(2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441415 · Cited by 330
Crohn's disease and cancer: A population-based cohort study
Persson, P.-G., Karlén, P., Bernell, O., Leijonmarck, C.-E., Broström, O., Ahlbom, A., & Hellers, G. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90807-9 · Cited by 306
Self-citationInflammatory bowel disease is not associated with an increased risk of lymphoma
Lewis, J. D., Bilker, W. B., Brensinger, C., Deren, J. J., Vaughn, D. J., & Strom, B. L. (2001) · Gastroenterology · doi:10.1053/gast.2001.28703 · Cited by 296
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients
Ricart, E., Panaccione, R., Loftus, E. V., Tremaine, W. J., & Sandborn, W. J. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03612.x · Cited by 285
Farrell, R. J., Ang, Y., Kileen, P., O'Briain, D. S., Kelleher, D., Keeling, P. W. N., & Weir, D. G. (2000) · Gut · doi:10.1136/gut.47.4.514 · Cited by 260
Inflammatory Bowel Disease Is Not Associated With An Increased Risk Of Lymphoma
&NA; (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200112000-00025 · Cited by 250
Cope, A. P., Londei, M., Chu, N. R., Cohen, S. B., Elliott, M. J., Brennan, F. M., Maini, R. N., & Feldmann, M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117394 · Cited by 243
Infliximab in Crohn's Disease: First Anniversary Clinical Experience
Cohen, R. D., Tsang, J. F., & Hanauer, S. B. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03363.x · Cited by 229
Extracolonic malignancies in inflammatory bowel disease
Ekbom, A., Helmick, C., Zack, M., & Adami, H.-O. (1991) · Cancer · doi:10.1002/1097-0142(19910401)67:7<2015::aid-cncr2820670731>3.0.co;2-r · Cited by 226
Clinical experience with infliximab therapy in 100 patients with Crohn's disease
Farrell, R. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02159-6 · Cited by 209
Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprine
Fraser, A. G., Orchard, T. R., Robinson, E. M., & Jewell, D. P. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01297.x · Cited by 198
HIF-1 expression in healing wounds: HIF-1α induction in primary inflammatory cells by TNF-α
Albina, J. E., Mastrofrancesco, B., Vessella, J. A., Louis, C. A., Henry, W. L., & Reichner, J. S. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.281.6.c1971 · Cited by 192
Jess, T., Winther, K. V., Munkholm, P., Langholz, E., & Binder, V. (2002) · Gastroenterology · doi:10.1053/gast.2002.33632 · Cited by 191
Survival and cause-specific mortality in inflammatory bowel disease: A population-based cohort study
Persson, P., Bernell, O., Leijonmarck, C., Farahmand, B., Hellers, G., & Ahlbom, A. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613037 · Cited by 174
Risk of lymphoma in inflammatory bowel disease
Loftus, E. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)01108-4 · Cited by 173
Infliximab for refractory ulcerative colitis
Chey, W. Y., Hussain, A., Ryan, C., Potter, G. D., & Shah, A. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.04039.x · Cited by 138
Inhibition of tumor necrosis factor‐α attenuates wound breaking strength in rats
Lee, R. H., Efron, D. T., Tantry, U., Stuelten, C., Moldawer, L. L., Abouhamze, A., & Barbul, A. (2000) · Wound Repair and Regeneration · doi:10.1046/j.1524-475x.2000.00547.x · Cited by 63
Infliximab for Crohn's disease in clinical practice at the Mayo clinic: The first 100 patients
Ricart, E., Panaccione, R., Loftus, E. V., et al. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)84405-4 · Cited by 45
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients
Ricart, E. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02405-9 · Cited by 31
Cited by
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Järnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Danielsson, Å., Verbaan, H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.003 · Cited by 1,089
Self-citationGuidelines for the management of inflammatory bowel disease in adults
Carter, M. J., Lobo, A. J., & Travis, S. P. L. (2004) · Gut · doi:10.1136/gut.2004.043372 · Cited by 1,083
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Chen, D. M., Pritchard, M. L., & Sandborn, W. J. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.002 · Cited by 905
Metadata
- Authors
- Ljung, T., Karlén, P., Schmidt, D., Hellström, P. M., Lapidus, A., Janczewska, I., Sjöqvist, U., & Löfberg, R.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2004-05-11
- Volume
- 53
- Issue
- 6
- Pages
- 849-853
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2054710465
- Cited by
- 313
- References
- 26
- FWCI
- 17.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.